SEARCH

SEARCH BY CITATION

References

  • 1
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815820.MEDLINE
  • 2
    Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167177.MEDLINE
  • 3
    Ghobrial RM, Colquhoun S, Rosen H, Hollis P, Ponthieux S, Pakrasi A, et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. Transplant Proc 1998; 30:14701471.MEDLINE
  • 4
    Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117:619625.MEDLINE
  • 5
    Lawrence SP. Advances in the treatment of hepatitis C. Adv Intern Med 2000; 45:65.MEDLINE
  • 6
    Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: A molecular and histologic study. Mod Pathol 2000; 13:229237.MEDLINE
  • 7
    Berenguer M, Wright TL. Hepatitis C virus in the transplant setting. Antivir Ther 1998; 3(suppl):S125.
  • 8
    Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. Gut 1999; 45:427434.MEDLINE
  • 9
    Casavilla FA, Rakela J, Kapur S, Irish W, McMichael J, Demetris A, et al. Clinical outcome of patients infected with hepatitis C virus on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998; 4:448454.MEDLINE
  • 10
    Bourgeois N. Hepatitis C recurrence after liver transplantation. Acta Gastroenterol Belg 1999; 62:428.MEDLINE
  • 11
    Boker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trrautwein C, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25:203210.MEDLINE
  • 12
    Platz KP, Mueller AR, Berg T, Neuhaus R, Hopf U, Lobeck H, et al. Searching for the optimal management of hepatitis C patients after liver transplantation. Transpl Int 1998; 11(suppl 1):S209S211.MEDLINE
  • 13
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:14531457.MEDLINE
  • 14
    Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:3034.MEDLINE
  • 15
    Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation. Surgery 1996; 119:452.MEDLINE
  • 16
    Liao HJ, Stollar V. Reversal of the antiviral activity of ribavirin against Sindbis virus in Ae. albopictus mosquito cells. Antiviral Res 1993; 22:285.MEDLINE
  • 17
    Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998; 42:3285.MEDLINE
  • 18
    Neyts J, De Clercq E. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antiviral Res 1998; 40:53.MEDLINE
  • 19
    Neyts J, Meerbach A, McKenna P, De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996; 30:125.MEDLINE
  • 20
    Birkeland SA, Andersen HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: Use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 67:1209.MEDLINE
  • 21
    Jain AB, Hamad I, Rakela J, Dodson SF, Kramer D, Demetris AJ, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: An interim report. Transplantation 1998; 66:13951398.MEDLINE
  • 22
    Jain A, Dodson F, Kramer D, Hamad I, Khan A, Eghestad B, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: A single center experience. Transplantation 2001; 72:1091.MEDLINE
  • 23
    Friedman LFC, Demeb A. Fundamentals of clinical trials. St Louis, MO: Mosby Year Book, 1985.
  • 24
    Demetris AJ, Batts KP, Dhillon AP, Ferrell L, Fung JJ, Geller DA, et al. Banff schema for grading liver allograft rejection. An international consensus document. Hepatology 1997; 25:658.MEDLINE
  • 25
    Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31:792799.MEDLINE
  • 26
    Demetris AJ, Dodson F. Hepatitis C in the liver allograft. Available at: http://tpis.upmc.edu/tpis/liver/ILACHepC.html. Accessed: September 1998.
  • 27
    Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696699.MEDLINE
  • 28
    Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42:216.MEDLINE
  • 29
    Fasola CME, Netto G, Jennings LW, Gonwa TA, Goldstein RM, Levy MF, Klintmalm G. Does mofetil mycophenolate (MMF) delay hepatitis C (Hep C) recurrence in liver transplant patients (OLTx) [abstract 123]? Liver Transpl 2000; 6:C31.
  • 30
    Smallwood GWT, Davis LP, Stieber AC, Heffron TG. Mycophenolate's influence on recurrence and outcomes of hepatitis C following liver transplantation. Transplantation 2000; 69:313.
  • 31
    Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. Transplant Proc 1998; 30:14681469.MEDLINE
  • 32
    Weppler D, Khan R, Fragulidis GP, Nery JR, Ricordi C, Tzakis AG. Status of liver and gastrointestinal transplantation at the University of Miami. In: Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory. 1996: 187201.
  • 33
    Kato T, Ruiz P, DeFaria W, Weppler D, Khan F, Pinna A, et al. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Transplant Proc 1999; 31:396.MEDLINE
  • 34
    Kato TNG, Montalbano M, Hung O, Lavendera R, Weppler D, Levi D, et al. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C—A preliminary report of a prospective randomized trial [abstract 174]. Am J Transplant 2001; 1:179.
  • 35
    Marino GRV, Marroquin C, Plotkin J, Kuo P, Lu A, Batty S, Johnson L. Early recurrence of hepatitis C after liver transplantation with daclizumab induction. Am J Transplant 2001; 1:188.